Fully Human Antibody Discovery Using Nanovials and Plasma Cells From ATX-GK™ Mice
Webinar Overview: Discover how to access previously untapped sources of high-affinity antibodies. In this presentation, Dr. Joe de Rutte from Partillion Bioscience and Dr. Dilip Challa from Alloy Therapeutics discuss how breakthrough technology can help: Access Plasma Cell Diversity: Discover how nanovial technology enables screening of plasma cells from ATX-GK transgenic mice harboring fully human […]
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation. BOSTON, Mass. – September 20, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and […]
Alloy Therapeutics to Empower Drug Discovery of Lundbeck’s Biologics for Brain Health
BOSTON, Mass. – May 2, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced it is collaborating with Lundbeck, a global pharmaceutical company specializing in brain diseases, in the discovery of novel biologics therapies. Through this agreement, Lundbeck will gain access to Alloy’s Antibody Discovery Services and its SeqImmune™ discovery module, which is a sequence-first workflow […]
Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents
Alloy Antibody Discovery Services offers partners a modular campaign design that can meet their goals and budgets as they collaborate to discover the best antibodies with therapeutic potential. BOSTON, Mass. – April 26, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the appointment of Kent Bondensgaard and John “Lippy” Lippincott as the latest members […]
Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology
— Partnership leverages Alloy’s high velocity antibody discovery offering to accelerate Normunity’s novel precision immuno-oncology pipeline — BOSTON, MA; November 17, 2022—Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing. The collaboration will support the […]
Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities
— Following a successful expansion from antibodies into T-cell receptors and genetic medicines, Alloy will broaden its pre-competitive discovery technology and discovery services to enable innovative new therapeutic formats — BOSTON, MA; October 03, 2022—Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala […]
ATX-Gx™ Biotech Licensee Discovering Novel Therapeutics
Alloy has more than 130 partners in the drug discovery ecosystem across academic, biotech, and large biopharma teams. Early in our history, we connected with Dren Bio, Inc., an emerging biopharmaceutical company headquartered in Northern California that specializes in the discovery of therapeutic antibodies engineered to selectively deplete pathologic cells and other disease-causing agents. Dren […]
Partnering with Target-Rich Biotech Companies
Running a successful early-stage biotech company requires a careful balance of enterprise and discipline. Companies must develop disruptive new discovery technologies or insights into disease biology that can have broad applications, but they must choose their first disease application(s) carefully. This tension is in large part driven by the demands around financing a startup biotech […]
Democratizing Access for Academic Entrepreneurs
We are advancing Alloy as a biotechnology ecosystem company, because we believe strongly that the innovation and breakthroughs that result from a network of relationships are far more powerful than those that can advance from silos. We collaborate with everyone to compete against disease. An exciting element of this dynamic is how under-resourced, smaller teams […]
Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning
Biotech ecosystem company Alloy Therapeutics leads the round, joined by Uncommon Denominator and Mytide founders BOSTON, March 8th, 2021–Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, has raised $7 million in Series A financing. The round was led by Alloy Therapeutics, a biotechnology ecosystem company, and was joined by Uncommon […]